Inventor · disambiguated record
Hua Ying
Also filed as: YING HUA
15 granted patents·24 pending applications·190 citations·filing 2007–2025
92Inventor score
Files withJIANGSU HENGRUI MEDICINE CO14JIANGSU HENGRUI PHARMACEUTICALS CO LTD10ABBVIE INC4MERCK SHARP & DOHME3ABBOTT LAB2
Top patents by PatentIndex Score
39 records- 0197US7915388B2Interleukin-13 binding proteinsABBOTT LAB·Filed 2007·Granted Mar 29, 2011·96 cites·41 claims
- 0294US9029508B2Dual variable domain immunoglobulins and uses thereofGHAYUR TARIQ·Filed 2009·Granted May 12, 2015·57 cites·22 claims
- 0392US12202891B2Antibody capable of binding to thymic stromal lymphopoietin and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2024·Granted Jan 21, 2025·2 cites·9 claims
- 0492US9592293B2Interleukin-13 binding proteinsABBVIE INC·Filed 2013·Granted Mar 14, 2017·18 cites·13 claims
- 0590US12258394B2IL-5 antibody, antigen binding fragment thereof, and medical application thereforJIANGSU HENGRUI MEDICINE CO·Filed 2022·Granted Mar 25, 2025·1 cites·13 claims
- 0687US11344621B2Interleukin-13 binding proteinsABBVIE INC·Filed 2018·Granted May 31, 2022·2 cites·35 claims
- 0787US11072658B2Anti-PD-1/LAG3 bispecific antibodiesMERCK SHARP & DOHME·Filed 2019·Granted Jul 27, 2021·5 cites·19 claims
- 0886US10086076B2Interleukin-13 binding proteinsABBVIE INC·Filed 2017·Granted Oct 2, 2018·4 cites·11 claims
- 0978US11365247B2IL-5 antibody, antigen binding fragment thereof, and medical application thereforJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Jun 21, 2022·1 cites·12 claims
- 1078US8604177B2Interleukin-13 binding proteinsWU CHENGBIN·Filed 2011·Granted Dec 10, 2013·3 cites·30 claims
- 1173US12258405B2CD3 antibody and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Mar 25, 2025·1 cites·14 claims
- 1268US2025333494A1Il-5 antibody, antigen binding fragment thereof, and medical application thereforJIANGSU HENGRUI MEDICINE CO·Filed 2025·Application pending·0 cites
- 1366US12404323B2Antibody capable of binding to thymic stromal lymphopoietin and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Granted Sep 2, 2025·0 cites·9 claims
- 1464US2021371530A1Anti-pd-1/lag3 bispecific antibodiesMERCK SHARP & DOHME·Filed 2021·Application pending·0 cites
- 1564US2025270303A1Anti-abeta antibody, antigen-binding fragment thereof and application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2025·Application pending·0 cites
- 1664US2021363256A1Anti-pd-1/lag3 bispecific antibodiesMERCK SHARP & DOHME·Filed 2021·Application pending·0 cites
- 1764US2025376519A1Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 1862US12325741B2Anti-Aβ antibodies and antigen-binding fragments thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Jun 10, 2025·0 cites·10 claims
- 1962US2025057968A1Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibodyJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2061US2025043022A1Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 2160US2024270874A1Anti-klb antibodies and usesJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2260US2024400670A1Anti-il23 antibody fusion protein and uses thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2358US2024301031A1Truncated taci polypeptide and fusion protein and use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2458US2024392020A1Antigen-binding moleculeJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2555US2024254245A1Antigen binding molecule specifically binding to rankl and ngf, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2654US12377163B2Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2019·Granted Aug 5, 2025·0 cites·40 claims
- 2754US2023055408A1Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Application pending·0 cites
- 2854US2025215083A1Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 2953US2023120270A1New polypeptide complexJIANGSU HENGRUI MEDICINE CO·Filed 2021·Application pending·0 cites
- 3051US2023013784A1Anti-cea antibody and application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Application pending·0 cites
- 3151US2010260668A1Dual Variable Domain Immunoglobulins and Uses ThereofABBOTT LAB·Filed 2009·Application pending·0 cites
- 3251US2015104452A1Dual variable domain immunoglobulins and uses thereofABBVIE INC·Filed 2014·Application pending·0 cites
- 3349US2023140397A1Anti-psma antibody-exatecan analogue conjugate and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3447US2023295313A1Il1rap binding proteinsGLAXOSMITHKLINE IP DEV LTD·Filed 2020·Application pending·0 cites
- 3546US12122834B2Anti-PD-1 antibodiesMERCK SHARP & DOHME LLC·Filed 2019·Granted Oct 22, 2024·0 cites·27 claims
- 3646US2022185875A1Bispecific antibody specifically bound to vegf and ang2JIANGSU HENGRUI MEDICINE CO·Filed 2020·Application pending·0 cites
- 3742US2020369774A1Il-6r antibody and antigen binding fragment thereof and medical useJIANGSU HENGRUI MEDICINE CO·Filed 2018·Application pending·0 cites
- 3839US2012195900A1Tri-variable domain binding proteins and uses thereofGHAYUR TARIQ·Filed 2011·Application pending·0 cites
- 3937US2019315886A1Thrombin antibody, antigen-binding fragment and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hua Ying files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →